MTOR and neoplasm: The use of targeted therapeutics such as VEGF, mTOR, c-kit or MEK inhibitors in cNF is likely based on data suggesting that these targets are important in NF1-deficient tumours.115–118 Additionally, the overlap between pathways dysregulated by NF1 loss and pathways dysregulated in other cancer types has also inspired clinical trials that reposition existing cancer treatment options.